Clinical Trials

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07179900 2025-12-11

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

60 enrolled

Carcinoma, Hepatocellular

NCT07254858 2025-11-28

CISN-L

302 enrolled

Breast

Breast Neoplasms

NCT07088731 2025-09-22

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Phase NA Not yet recruiting

180 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

234 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT07053150 2025-07-08

CCGLC-018

80 enrolled

Advanced Digestive System Tumor

NCT07018063 2025-06-12

YOUNG-NEOS

35 enrolled

Phase 4 Not yet recruiting

Neoplasms, Stomach Neoplasms

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

Thyroid Neoplasms

NCT07007767 2025-06-06

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

32 enrolled

Phase 2/3 Not yet recruiting

Colorectal Cancer Metastatic

NCT06977061 2025-05-16

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

Stomach Neoplasms

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

664 enrolled

Phase 1/2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06888648 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Phase 1/2 Not yet recruiting

Pancreatic Cancer Metastatic

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

60 enrolled

Pancreatic Cancer Resectable

NCT06837948 2025-02-20

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

160 enrolled

Locally Advanced Non-Small Cell Lung Cancer

NCT05562297 2025-01-22

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

50 enrolled

Pancreatic Neoplasms

NCT06747169 2024-12-27

Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

32 enrolled

Squamous Non-Small Cell Lung Cancer SqNSCLC

NCT06748508 2024-12-27

FDZL-GC003

141 enrolled

Stomach Neoplasms

NCT06697366 2024-11-20

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

27 enrolled

Stomach Neoplasms

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06688656 2024-11-14

Peri-E

Lung Neoplasms

NCT06680115 2024-11-08

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

150 enrolled

Nasopharyngeal Carcinoma

NCT06652412 2024-10-28

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

124 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT06620822 2024-10-01

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

296 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06604351 2024-09-19

Example

39 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06564298 2024-08-28

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

39 enrolled

Phase NA Not yet recruiting

Stomach Neoplasms

NCT06549855 2024-08-12

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

10 enrolled

Gynecologic

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT06523049 2024-07-26

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Phase 4 Not yet recruiting

67 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06499610 2024-07-12

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

44 enrolled

Stomach Neoplasms

NCT06485557 2024-07-03

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

90 enrolled

Resectable Non-small Cell Lung Cancer

NCT06454435 2024-06-12

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

158 enrolled

Stomach Neoplasms

NCT06447636 2024-06-07

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

20 enrolled

Stomach Neoplasms

NCT06408623 2024-05-10

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

48 enrolled

Liver Neoplasms

NCT06089369 2024-04-30

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

360 enrolled

Carcinoma, Hepatocellular

NCT06364826 2024-04-15

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

60 enrolled

Nasopharyngeal Carcinoma

NCT06308939 2024-03-13

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

81 enrolled

Breast

Breast Neoplasms

NCT06221462 2024-01-25

PRIORITY

Carcinoma, Non-Small-Cell Lung

NCT06198907 2024-01-10

JACKPOT33

69 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06195670 2024-01-08

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

220 enrolled

Colorectal Neoplasms

NCT06152978 2023-12-01

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

182 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06094868 2023-10-23

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

45 enrolled

Stomach Neoplasms

NCT06089382 2023-10-18

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

104 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Hepatocellular

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

668 enrolled

Carcinoma, Hepatocellular

NCT05244798 2022-10-25

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

420 enrolled

Esophageal Squamous Cell Carcinoma

NCT05507632 2022-08-19

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

48 enrolled

Carcinoma, Hepatocellular

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

93 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP